Literature DB >> 2525131

The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system.

V J Miralles1, P Cortes, N Stone, D Reinberg.   

Abstract

Two binding sites for EivF, a factor involved in transcription from the adenovirus early promoter iv (Eiv), were mapped within the adenovirus inverted terminal repeats (ITR). Consistent with the observation that EivF was required to initiate transcription from the Eiv promoter and with the demonstration that two EivF binding sites were present in the ITR, we show that the inverted terminal repeat region was able to promote transcription from the CAP site of the Eiv promoter in vitro and in an EIa-dependent fashion in vivo. The minimum sequence within the ITR capable of directing EIa-dependent transcription consists of forty nine nucleotides comprising two EivF binding sites and at least one Sp1 binding site. This 49-base pair fragment possesses the characteristics of an enhancer which is induced by EIa. The enhancer is active in HeLa cell nuclear extracts. Transcription directed by the ITR required EivF and the general transcription factors. The addition of purified Sp1 factor specifically stimulated transcription which correlates with the presence of Sp1 binding sites between the two EivF recognition sites.

Mesh:

Substances:

Year:  1989        PMID: 2525131

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Termination of transcription in an 'in vitro' system is dependent on a polyadenylation sequence.

Authors:  V J Miralles
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

2.  Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection.

Authors:  J T Bruder; P Hearing
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

3.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

4.  Insufficient levels of NFIII and its low affinity for the origin of adenovirus type 12 (Ad12) DNA replication contribute to the abortive infection of BHK21 hamster cells by Ad12.

Authors:  G Schiedner; W Doerfler
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 5.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

6.  Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.

Authors:  Hong-Duck Kim; Jing-Ji Jin; J Adam Maxwell; Ken-ichiro Fukuchi
Journal:  Immunol Lett       Date:  2007-07-23       Impact factor: 3.685

7.  Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.

Authors:  Robert J Rooney
Journal:  Gene       Date:  2020-06-11       Impact factor: 3.688

8.  The NFIII/OCT-1 binding site stimulates adenovirus DNA replication in vivo and is functionally redundant with adjacent sequences.

Authors:  L Hatfield; P Hearing
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  E1A-mediated activation of the adenovirus E4 promoter can occur independently of the cellular transcription factor E4F.

Authors:  C Jones; K A Lee
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

10.  TPA can overcome the requirement for EIa and together act synergistically in stimulating expression of the adenovirus EIII promoter.

Authors:  L Buckbinder; V J Miralles; D Reinberg
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.